Lacosamide Vivanta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyper‑excitable neurons, limits repetitive firing, and thereby reduces the propagation of epileptic activity without markedly affecting normal nerve conduction.

The specific dose and infusion rate of Lacosamide Vivanta are determined by the prescribing clinician based on the patient’s clinical condition, age, weight, renal function, and concomitant therapies. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

The safety of lacosamide during pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a qualified obstetrician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation, which may result in a different side‑effect profile and fewer drug‑interaction concerns. However, therapeutic decisions depend on individual patient factors, seizure type, and tolerability.

Lacosamide Vivanta must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it may still be used, but it should be returned to the refrigerator promptly.

Lacosamide Vivanta is given by intravenous infusion. The recommended infusion rate and total daily dose are set by the treating physician. The solution is typically diluted in compatible IV fluids and administered over a controlled period to minimise infusion‑related reactions.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviours, and anaphylactic reactions. Patients should be monitored for these signs, especially during initiation and dose escalation.

Lacosamide Vivanta is contraindicated in patients with known hypersensitivity to lacosamide or any excipients in the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking interacting medications that could markedly alter lacosamide levels.